Key facts
- It has raised $310K; the latest was Seed Round ($80K) in Feb 2026.
- Notable investors include Techstars.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Cytodyme
- ·The full record, as it builds
Funding rounds
No funding rounds for Cytodyme are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cytodyme
Developer of a clinical development platform designed to focus life-science and biotech companies on clinical development and regulatory compliance. The company's platform utilizes AI to generate, organize, update, and manage regulatory documents such as SOPs, batch records, material specifications, and regulatory reports like IND submissions, change controls, ensuring accuracy by applying formatting, while also identifying missing or incomplete documents and adhering to standards, enabling biotech teams to streamline workflows, maintain compliance, and accelerate documentation review and finalization.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2024
- Employees
- 5
- Website
- cytodyme.com/
- Ownership
- Privately Held (backing)
Cytodyme doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cytodyme shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cytodyme in its N-PORT filings yet. We sweep new filings monthly.